These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36254617)

  • 1. A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC.
    Larrey E; Campion B; Evain M; Sultanik P; Blaise L; Giudicelli H; Wagner M; Cluzel P; Rudler M; Ganne-Carrié N; Thabut D; Allaire M
    Liver Int; 2022 Dec; 42(12):2843-2854. PubMed ID: 36254617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey.
    Allaire M; Manfredi S; Lerosey L; Ganne-Carrié N; Thabut D
    Clin Res Hepatol Gastroenterol; 2023 Feb; 47(2):102059. PubMed ID: 36455860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab.
    Sultanik P; Campani C; Larrey E; Campion B; Evain M; Roux C; Blaise L; Wagner M; Rudler M; Nault JC; Thabut D; Allaire M
    Dig Liver Dis; 2024 Sep; 56(9):1621-1630. PubMed ID: 38548580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC.
    Chaibi S; Larrey E; Couty JP; Sultanik P; Campani C; Blaise L; Wagner M; Desdouets C; Nault JC; Thabut D; Allaire M
    Clin Res Hepatol Gastroenterol; 2023 Oct; 47(8):102199. PubMed ID: 37666414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCC portal hypertension imaging score derived from CT predicts re-bleeding and mortality after acute variceal bleeding.
    Zhao M; Zhang B; Shi J; Tang X; Li H; Li S; Yang Y; Han Y; Wang R; Xun J; Zhang K; Wu X; Zhao J
    Cancer Imaging; 2024 Mar; 24(1):45. PubMed ID: 38549132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Portal-hypertension features are associated with ascites occurrence and survival in patients with hepatocellular carcinoma treated by external radiotherapy.
    Giudicelli H; Andraud M; Wagner M; Bourdais R; Goumard C; Scatton O; Thabut D; Simon JM; Allaire M
    United European Gastroenterol J; 2023 Dec; 11(10):985-997. PubMed ID: 38018771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports.
    Yeom KM; Song YG; Yoo JJ; Kim SG; Kim YS
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256417
    [No Abstract]   [Full Text] [Related]  

  • 8. Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study.
    Lim J; Kim HI; Kim E; Kim J; An J; Chang S; Kim SO; Lee HC; Lee YS; Shim JH
    BMC Cancer; 2021 Jan; 21(1):11. PubMed ID: 33402105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
    Furusawa A; Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Hatanaka T; Kakizaki S
    Clin J Gastroenterol; 2022 Apr; 15(2):451-459. PubMed ID: 35179703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of portal hypertension after atezolizumab plus bevacizumab for hepatocellular carcinoma-report a case and literature review.
    Lin TY; Su TH
    J Formos Med Assoc; 2024 Aug; 123(8):916-919. PubMed ID: 38565487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clinical outcomes between variceal and non-variceal gastrointestinal bleeding in patients with cirrhosis.
    Tandon P; Bishay K; Fisher S; Yelle D; Carrigan I; Wooller K; Kelly E
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1773-1779. PubMed ID: 29601652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic Venous Pressure Gradient Predicts Further Decompensation in Cirrhosis Patients with Acute Esophageal Variceal Bleeding.
    Vaishnav M; Biswas S; Anand A; Pathak P; Swaroop S; Aggarwal A; Arora U; Elhence A; Gamanagatti S; Goel A; Kumar R; Shalimar
    Diagnostics (Basel); 2023 Jul; 13(14):. PubMed ID: 37510129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
    Fulgenzi CAM; Cheon J; D'Alessio A; Nishida N; Ang C; Marron TU; Wu L; Saeed A; Wietharn B; Cammarota A; Pressiani T; Personeni N; Pinter M; Scheiner B; Balcar L; Napolitano A; Huang YH; Phen S; Naqash AR; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; Sharma R; Cortellini A; Gaillard VE; Chon HJ; Pinato DJ
    Eur J Cancer; 2022 Nov; 175():204-213. PubMed ID: 36148739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of in-hospital mortality after acute variceal bleeding in patients with hepatocellular carcinoma and concurrent main portal vein thrombosis.
    Han ML; Chen CC; Kuo SH; Hsu WF; Liou JM; Wu MS; Wang HP
    J Gastroenterol Hepatol; 2014 Feb; 29(2):344-51. PubMed ID: 23870023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duodenal Variceal Rupture during Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma.
    Tsuruoka M; Inoue J; Ouchi K; Uno K; Itami H; Ninomiya M; Iwata T; Sano A; Sato K; Onuki M; Sawahashi S; Koike T; Masamune A
    Intern Med; 2023 May; 62(10):1467-1472. PubMed ID: 36198602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher free serum cortisol is associated with worse survival in acute variceal bleeding because of cirrhosis: a prospective study.
    Triantos CK; Kalafateli M; Samonakis D; Zisimopoulos K; Papiamonis N; Sapountzis A; Michalaki M; Theocharis G; Thomopoulos K; Labropoulou-Karatza C; Kyriazopoulou V; Jelastopulu E; Kouroumalis EA; Nikolopoulou V; Burroughs AK
    Eur J Gastroenterol Hepatol; 2014 Oct; 26(10):1125-32. PubMed ID: 25089543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management.
    Allaire M; Thabut D
    Hepatology; 2024 Jan; 79(1):213-223. PubMed ID: 36631021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables.
    Eslam M; Ampuero J; Jover M; Abd-Elhalim H; Rincon D; Shatat M; Camacho I; Kamal A; Lo Iacono O; Nasr Z; Grande L; Banares R; Khattab MA; Romero-Gomez M
    Ann Hepatol; 2013; 12(4):588-98. PubMed ID: 23813137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.